Gefurulimab (mAbID 1253), a bispecific VH-VH mAb that binds to C5 (to inhibit complement cascade) and albumin (to extend antibody half-life), are currently under clinical development for the treatment of gMG, along with dermatomyositis and proteinuria. The gene discussed is C5; the disease is dermatomyositis.